A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
N/A
Synonyms :
asnuciclib, CDKI-73, LS-007
Class :
Antineoplastic agents, CDK-9 inhibitors
Dosage forms and strength Â
It is an investigational drug studied for its effectiveness to treat primary leukemia
Pediatric Â
Not determined Â
Actions and spectrum:Â Â
Asnuciclib is a CDK9 inhibitor. It inhibits the phosphorylation of RNAPII. It is an innovative pharmacological inhibitor of innate immune secretion and Rab11 cargo delivery.Â
None Â
Black box warning Â
None Â
Contraindication/Caution:Â Â
None Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Pharmacology:Â Â
Asnuciclib is a potential inhibitor of CDK9. It is a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion.Â
Pharmacodynamics:Â Â
Asnuciclib exhibits an affinity for primary cells of leukemia and is highly cytotoxic to these cells which are derived from chronic lymphatic leukemia patients (CLL). Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
The route of administration is not fully known. Â
Patient information leaflet Â
Generic Name: asnuciclib Â
Why do we use asnuciclib? Â
Asnuciclib is an antineoplastic agent thus its efficacy has been studied in treatment of primary leukemia. Â